Author:
Williamson Stephen K.,Johnson Gary A.,Maulhardt Holly A.,Moore Kathleen M.,McMeekin D. S.,Schulz Thomas K.,Reed Gregory A.,Roby Katherine F.,Mackay Christine B.,Smith Holly J.,Weir Scott J.,Wick Jo A.,Markman Maurie,diZerega Gere S.,Baltezor Michael J.,Espinosa Jahna,Decedue Charles J.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference36 articles.
1. NCI (2014) SEER stat fact sheets: ovary cancer (SEER 18 2004-2010). http://seer.cancer.gov/statfacts/html/ovary.html . Accessed 25 July 2014
2. Szebeni J, Alving CR, Muggia FM (1998) Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 90(4):300–306. doi: 10.1093/jnci/90.4.300
3. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC (1993) Clinical toxicities encountered with paclitaxel (TAXOL®). Semin Oncol 20(4, Suppl 3):1–15
4. Jacquet P, Sugarbaker PH (1996) Peritoneal-plasma barrier. In: Sugarbaker PH (ed) Peritoneal carcinomatosis: principles of management. Kluwer Academic Publishers, Boston, pp 53–63
5. Yan TD, Cao CQ, Munkholm-Larsen S (2010) A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy. World J Gastrointest Oncol 2(2):109–116. doi: 10.4251/wjgo.v2.i2.109
Cited by
58 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献